CNTA
Centessa Pharmaceuticals plc$40.49+0.00 (—)Prev Close$40.18·MCap$3.51B·P/E—·Vol—·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
16
$6.50M
◆
Net Activity
Net Seller
$6.50M
●
Active Insiders
5
last 12 mo
Over the past 12 months, insider activity at Centessa Pharmaceuticals plc (CNTA) has been exclusively selling, with 0 insider purchases totaling $0.00 and 16 insider sales totaling $6.50M. The most recent insider transaction was by Accardi Mario Alberto (Chief Executive Officer), who sold $71.6K worth of shares on Feb 1, 2026. Centessa Pharmaceuticals plc operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $3.51B.
CNTA Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 1, 2026 | Accardi Mario Alberto | Chief Executive Officer | Sell | 2,915 | $24.57 | $71.6K | 0 |
| Feb 1, 2026 | Anderson Karen M. | Chief People Officer | Sell | 10,606 | $24.57 | $260.6K | 0 |
| Feb 1, 2026 | Bush Tia L | Chief Technology & Quality Ofc | Sell | 8,549 | $24.57 | $210.0K | 0 |
| Feb 1, 2026 | Weinhoff Gregory M | Chief Business Officer | Sell | 14,158 | $24.57 | $347.9K | 0 |
| Jan 30, 2026 | HUSSAIN IQBAL J | Chief Legal Officer | Sell | 47,741 | $25.05 | $1.20M | 0 |
| Dec 9, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 10,000 | $28.83 | $288.3K | 0 |
| Dec 8, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 10,000 | $30.00 | $300.0K | 0 |
| Nov 17, 2025 | Bush Tia L | Chief Technology & Quality Ofc | Sell | 40,000 | $28.00 | $1.12M | 0 |
| Nov 17, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 6,000 | $27.64 | $165.8K | 0 |
| Nov 12, 2025 | Bush Tia L | Chief Technology & Quality Ofc | Sell | 40,000 | $26.00 | $1.04M | 0 |
| Nov 1, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 593 | $24.90 | $14.8K | 0 |
| Oct 27, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 8,000 | $25.00 | $200.0K | 0 |
| Oct 15, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 6,000 | $22.41 | $134.4K | 0 |
| Sep 24, 2025 | Bush Tia L | Chief Technology & Quality Ofc | Sell | 35,000 | $24.00 | $840.0K | 0 |
| Sep 16, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 8,172 | $21.40 | $174.8K | 0 |
| Sep 15, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 6,000 | $21.85 | $131.1K | 0 |
| Sep 9, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 7,000 | $20.00 | $140.0K | 0 |
| Sep 9, 2025 | Bush Tia L | Chief Technology & Quality Ofc | Sell | 49,792 | $21.00 | $1.05M | 0 |
| Sep 9, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 40,000 | $21.00 | $840.1K | 0 |
| Aug 15, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 6,000 | $17.23 | $103.4K | 0 |
| Aug 1, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 597 | $17.17 | $10.3K | 0 |
| Jul 29, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 8,322 | $15.23 | $126.8K | 0 |
| Jul 25, 2025 | Weinhoff Gregory M | Chief Business Officer | Sell | 10,000 | $15.56 | $155.6K | 0 |
| Jul 21, 2025 | SAHA SAURABH | Chief Executive Officer | Sell | 55,000 | $15.92 | $875.6K | 0 |
| Jul 15, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 6,000 | $14.93 | $89.6K | 0 |
| Jun 25, 2025 | Weinhoff Gregory M | Chief Business Officer | Sell | 10,000 | $13.86 | $138.6K | 0 |
| Jun 24, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 15,000 | $14.00 | $210.0K | 0 |
| Jun 24, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 12,000 | $14.02 | $168.2K | 0 |
| Jun 20, 2025 | SAHA SAURABH | Chief Executive Officer | Sell | 55,000 | $12.63 | $694.8K | 0 |
| May 27, 2025 | Weinhoff Gregory M | Chief Business Officer | Sell | 10,000 | $12.82 | $128.2K | 0 |
| May 20, 2025 | SAHA SAURABH | Chief Executive Officer | Sell | 55,000 | $12.71 | $699.1K | 0 |
| May 15, 2025 | GOYAL ARJUN | Director | Buy | 462,585 | $12.68 | $5.87M | 0 |
| May 1, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 311 | $14.00 | $4.4K | 0 |
| Apr 25, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 5,689 | $14.00 | $79.7K | 0 |
| Apr 25, 2025 | Weinhoff Gregory M | Chief Business Officer | Sell | 11,742 | $13.61 | $159.9K | 0 |
| Apr 21, 2025 | SAHA SAURABH | Chief Executive Officer | Sell | 55,000 | $12.39 | $681.6K | 0 |
| Mar 25, 2025 | Weinhoff Gregory M | Chief Business Officer | Sell | 10,000 | $16.34 | $163.4K | 0 |
| Mar 20, 2025 | SAHA SAURABH | Chief Executive Officer | Sell | 55,000 | $16.69 | $918.1K | 0 |
| Mar 17, 2025 | CHAO DAVID M | Chief Administrative Officer | Sell | 7,000 | $17.17 | $120.2K | 0 |
| Mar 17, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 6,000 | $16.45 | $98.7K | 0 |
| Feb 25, 2025 | Weinhoff Gregory M | Chief Business Officer | Sell | 11,494 | $15.25 | $175.3K | 0 |
| Feb 20, 2025 | SAHA SAURABH | Chief Executive Officer | Sell | 55,000 | $15.93 | $876.1K | 0 |
| Feb 18, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 6,000 | $16.18 | $97.1K | 0 |
| Feb 7, 2025 | Anderson Karen M. | Chief People Officer | Sell | 30,955 | $19.03 | $588.9K | 0 |
| Feb 1, 2025 | Anderson Karen M. | Chief People Officer | Sell | 17,203 | $16.90 | $290.7K | 0 |
| Feb 1, 2025 | Bush Tia L | Chief Technology & Quality Ofc | Sell | 19,693 | $16.88 | $332.5K | 0 |
| Feb 1, 2025 | CHAO DAVID M | Chief Administrative Officer | Sell | 13,324 | $16.92 | $225.4K | 0 |
| Feb 1, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 12,879 | $16.92 | $217.9K | 0 |
| Feb 1, 2025 | SAHA SAURABH | Chief Executive Officer | Sell | 43,381 | $16.92 | $734.0K | 0 |
| Feb 1, 2025 | Weinhoff Gregory M | Chief Business Officer | Sell | 14,267 | $16.92 | $241.4K | 0 |
Showing 1–50 of 174
1 / 4
CNTA Insider Buying Activity
The following table shows recent insider purchases of Centessa Pharmaceuticals plc (CNTA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 15, 2025 | GOYAL ARJUN | Director | Buy | 462,585 | $12.68 | $5.87M | 0 |
CNTA Insider Selling Activity
The following table shows recent insider sales of Centessa Pharmaceuticals plc (CNTA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 1, 2026 | Accardi Mario Alberto | Chief Executive Officer | Sell | 2,915 | $24.57 | $71.6K | 0 |
| Feb 1, 2026 | Anderson Karen M. | Chief People Officer | Sell | 10,606 | $24.57 | $260.6K | 0 |
| Feb 1, 2026 | Bush Tia L | Chief Technology & Quality Ofc | Sell | 8,549 | $24.57 | $210.0K | 0 |
| Feb 1, 2026 | Weinhoff Gregory M | Chief Business Officer | Sell | 14,158 | $24.57 | $347.9K | 0 |
| Jan 30, 2026 | HUSSAIN IQBAL J | Chief Legal Officer | Sell | 47,741 | $25.05 | $1.20M | 0 |
| Dec 9, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 10,000 | $28.83 | $288.3K | 0 |
| Dec 8, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 10,000 | $30.00 | $300.0K | 0 |
| Nov 17, 2025 | Bush Tia L | Chief Technology & Quality Ofc | Sell | 40,000 | $28.00 | $1.12M | 0 |
| Nov 17, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 6,000 | $27.64 | $165.8K | 0 |
| Nov 12, 2025 | Bush Tia L | Chief Technology & Quality Ofc | Sell | 40,000 | $26.00 | $1.04M | 0 |
| Nov 1, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 593 | $24.90 | $14.8K | 0 |
| Oct 27, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 8,000 | $25.00 | $200.0K | 0 |
| Oct 15, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 6,000 | $22.41 | $134.4K | 0 |
| Sep 24, 2025 | Bush Tia L | Chief Technology & Quality Ofc | Sell | 35,000 | $24.00 | $840.0K | 0 |
| Sep 16, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 8,172 | $21.40 | $174.8K | 0 |
| Sep 15, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 6,000 | $21.85 | $131.1K | 0 |
| Sep 9, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 7,000 | $20.00 | $140.0K | 0 |
| Sep 9, 2025 | Bush Tia L | Chief Technology & Quality Ofc | Sell | 49,792 | $21.00 | $1.05M | 0 |
| Sep 9, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 40,000 | $21.00 | $840.1K | 0 |
| Aug 15, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 6,000 | $17.23 | $103.4K | 0 |
| Aug 1, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 597 | $17.17 | $10.3K | 0 |
| Jul 29, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 8,322 | $15.23 | $126.8K | 0 |
| Jul 25, 2025 | Weinhoff Gregory M | Chief Business Officer | Sell | 10,000 | $15.56 | $155.6K | 0 |
| Jul 21, 2025 | SAHA SAURABH | Chief Executive Officer | Sell | 55,000 | $15.92 | $875.6K | 0 |
| Jul 15, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 6,000 | $14.93 | $89.6K | 0 |
| Jun 25, 2025 | Weinhoff Gregory M | Chief Business Officer | Sell | 10,000 | $13.86 | $138.6K | 0 |
| Jun 24, 2025 | Accardi Mario Alberto | President, Orexin Program | Sell | 15,000 | $14.00 | $210.0K | 0 |
| Jun 24, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 12,000 | $14.02 | $168.2K | 0 |
| Jun 20, 2025 | SAHA SAURABH | Chief Executive Officer | Sell | 55,000 | $12.63 | $694.8K | 0 |
| May 27, 2025 | Weinhoff Gregory M | Chief Business Officer | Sell | 10,000 | $12.82 | $128.2K | 0 |
| May 20, 2025 | SAHA SAURABH | Chief Executive Officer | Sell | 55,000 | $12.71 | $699.1K | 0 |
| May 1, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 311 | $14.00 | $4.4K | 0 |
| Apr 25, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 5,689 | $14.00 | $79.7K | 0 |
| Apr 25, 2025 | Weinhoff Gregory M | Chief Business Officer | Sell | 11,742 | $13.61 | $159.9K | 0 |
| Apr 21, 2025 | SAHA SAURABH | Chief Executive Officer | Sell | 55,000 | $12.39 | $681.6K | 0 |
| Mar 25, 2025 | Weinhoff Gregory M | Chief Business Officer | Sell | 10,000 | $16.34 | $163.4K | 0 |
| Mar 20, 2025 | SAHA SAURABH | Chief Executive Officer | Sell | 55,000 | $16.69 | $918.1K | 0 |
| Mar 17, 2025 | CHAO DAVID M | Chief Administrative Officer | Sell | 7,000 | $17.17 | $120.2K | 0 |
| Mar 17, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 6,000 | $16.45 | $98.7K | 0 |
| Feb 25, 2025 | Weinhoff Gregory M | Chief Business Officer | Sell | 11,494 | $15.25 | $175.3K | 0 |
| Feb 20, 2025 | SAHA SAURABH | Chief Executive Officer | Sell | 55,000 | $15.93 | $876.1K | 0 |
| Feb 18, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 6,000 | $16.18 | $97.1K | 0 |
| Feb 7, 2025 | Anderson Karen M. | Chief People Officer | Sell | 30,955 | $19.03 | $588.9K | 0 |
| Feb 1, 2025 | Anderson Karen M. | Chief People Officer | Sell | 17,203 | $16.90 | $290.7K | 0 |
| Feb 1, 2025 | Bush Tia L | Chief Technology & Quality Ofc | Sell | 19,693 | $16.88 | $332.5K | 0 |
| Feb 1, 2025 | CHAO DAVID M | Chief Administrative Officer | Sell | 13,324 | $16.92 | $225.4K | 0 |
| Feb 1, 2025 | HUSSAIN IQBAL J | General Counsel | Sell | 12,879 | $16.92 | $217.9K | 0 |
| Feb 1, 2025 | SAHA SAURABH | Chief Executive Officer | Sell | 43,381 | $16.92 | $734.0K | 0 |
| Feb 1, 2025 | Weinhoff Gregory M | Chief Business Officer | Sell | 14,267 | $16.92 | $241.4K | 0 |
CNTA Insiders
Similar Stocks to CNTA
VRTX
Vertex Pharmaceuticals Incorporated
$519.60+0.81%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$796.65+1.94%
$83.21B
MRNA
Moderna, Inc.
$147.00+2.12%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.27+0.25%
$44.15B
INSM
Insmed Incorporated
$125.24-3.18%
$28.05B
INCY
Incyte Corporation
$123.24+1.32%
$24.62B
UTHR
United Therapeutics Corporation
$504.37+1.48%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$157.78+1.00%
$15.71B